Please login to the form below

Not currently logged in
Email:
Password:

NICE recommends Allergan eye implant

Allergan’s Ozurdex eye implant to treat macular oedema has been approved for use by the UK’s NHS in draft guidance from the National Institute for Health and Clinical Excellence

Allergan's Ozurdex (dexamethasone) eye implant to treat macular oedema has been approved for use by the UK's NHS in draft guidance from the National Institute for Health and Clinical Excellence (NICE).

The implant is approved in patients with macular oedema following central retinal vein occlusion (CRVO) or following branch retinal vein occlusion (BRVO) when treatment with laser photocoagulation has not been beneficial or is not suitable.

RVO is the blockage of a blood vessel in the retina so blood cannot drain out. This can lead to damage of an individual's eyesight.

Ozurdex works by suppressing inflammation in the eye, and is injected every six months.

Final guidance is due to be published in July 2011, with registered stakeholders able to appeal against the draft recommendations.

The announcement follows the news that Novartis' wet age-related macular degeneration treatment Lucentis (ranibizumab injection) has been approved for a new indication of vision loss due to macular oedema following RVO by the European Commission.

Ozurdex was approved by the European Medicines Agency (EMA) in 2010 as the first treatment authorised in Europe for the treatment for its current indication.

7th June 2011

From: Healthcare

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics